Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), recently executed a series of stock ...

Liquidia Corporation's litigation battle and upcoming commercial launch of its primary candidate, YUTREPIA, take spotlight.

United Therapeutics could eventually use the genetically edited swine to grow organs for human transplant recipients. A ...

Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), recently executed a series of stock transactions involving the company's common stock. On January 21, Benkowitz sold ...

United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of unique products to address the unmet medical needs of patients with chronic ...

Per filings with the Texas Deparment of Licensing and Regulation, United Therapeutics will construct a 77,448-square-foot facility at 11848 Common Dock Dr. "that will house two types of ...

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life ...

The management’s strategic focus on these areas, alongside their ability to efficiently progress through clinical trials, positions United Therapeutics well for substantial growth in the ...

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the world’s first transplant of ...